DE69526216T2 - Antifungaleverfahren und mitteln - Google Patents

Antifungaleverfahren und mitteln

Info

Publication number
DE69526216T2
DE69526216T2 DE69526216T DE69526216T DE69526216T2 DE 69526216 T2 DE69526216 T2 DE 69526216T2 DE 69526216 T DE69526216 T DE 69526216T DE 69526216 T DE69526216 T DE 69526216T DE 69526216 T2 DE69526216 T2 DE 69526216T2
Authority
DE
Germany
Prior art keywords
antifungal
procedure
fungal infection
bpi
bactericidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526216T
Other languages
English (en)
Other versions
DE69526216D1 (de
Inventor
Roger G Ii Little
Edward Lim
J Scannon
H Lambert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Technology Ltd USA
Original Assignee
Xoma Technology Ltd USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/209,762 external-priority patent/US5733872A/en
Application filed by Xoma Technology Ltd USA filed Critical Xoma Technology Ltd USA
Application granted granted Critical
Publication of DE69526216D1 publication Critical patent/DE69526216D1/de
Publication of DE69526216T2 publication Critical patent/DE69526216T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69526216T 1994-01-14 1995-01-13 Antifungaleverfahren und mitteln Expired - Fee Related DE69526216T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18322294A 1994-01-14 1994-01-14
US08/209,762 US5733872A (en) 1993-03-12 1994-03-11 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US27354094A 1994-07-11 1994-07-11
PCT/US1994/010427 WO1995019372A1 (en) 1994-01-14 1994-09-15 Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
PCT/US1995/000498 WO1995019179A1 (en) 1994-01-14 1995-01-13 Anti-fungal methods and materials

Publications (2)

Publication Number Publication Date
DE69526216D1 DE69526216D1 (de) 2002-05-08
DE69526216T2 true DE69526216T2 (de) 2002-11-14

Family

ID=27391654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526216T Expired - Fee Related DE69526216T2 (de) 1994-01-14 1995-01-13 Antifungaleverfahren und mitteln

Country Status (11)

Country Link
US (1) US5627153A (de)
EP (1) EP0754049B1 (de)
JP (1) JPH09508357A (de)
CN (1) CN1112933C (de)
AT (1) ATE215379T1 (de)
AU (1) AU703211B2 (de)
CA (1) CA2181165C (de)
DE (1) DE69526216T2 (de)
HK (1) HK1014158A1 (de)
MX (1) MX9602570A (de)
WO (1) WO1995019179A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
AU709738B2 (en) * 1994-09-15 1999-09-02 Xoma Corporation Anti-fungal peptides
AU727085B2 (en) * 1995-07-20 2000-11-30 Xoma Corporation Anti-fungal peptides
US5851802A (en) * 1996-03-22 1998-12-22 Xoma Corporation Methods for recombinant microbial production of fusion proteins and BPI-derived peptides
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
DE69719754D1 (de) * 1996-05-23 2003-04-17 Xoma Technology Ltd Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
USRE38984E1 (en) * 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
US6482796B2 (en) * 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
US6706688B2 (en) 2001-03-09 2004-03-16 Paula Sundstrom Methods for regulating bud-hypha transitions and cAMP levels by the adenylate cyclase-associated protein gene, CAP1
US7270975B2 (en) * 2001-03-09 2007-09-18 Trustees Of Dartmouth College Methods for regulating bud-hypha transitions and cAMP levels in Candida albicans
EP1730180A4 (de) * 2004-02-24 2008-06-18 Commw Scient Ind Res Org Gegen pilze wirkende peptide
WO2006120496A1 (fr) * 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
EP1741440A1 (de) 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
CN104745595B (zh) * 2015-03-27 2017-06-27 宁波大学 刺参bpi基因、编码蛋白及其克隆方法和重组刺参bpi基因工程菌构建方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5087569A (en) * 1986-11-26 1992-02-11 Cornell Research Foundation, Inc. And The Rockefeller University Antimicrobial proteins, compositions containing same and uses thereof
US5126257A (en) * 1986-11-26 1992-06-30 Cornell Research Foundation Antimicrobial proteins, compositions containing same and uses thereof
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
EP0563222B1 (de) * 1990-12-03 1998-02-25 New York University Biologisch aktive bakterizide/permeabilitätserhöhende proteinbruchstücke
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
EP0642579B1 (de) * 1992-05-19 1999-04-07 Xoma Corporation Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DE69428521T2 (de) * 1993-02-02 2002-05-23 Xoma Technology Ltd Arzneizusammensetzungen enthaltend ein bakterizides permeabilität erhöhendes protein und ein tensid
ATE202482T1 (de) * 1993-03-12 2001-07-15 Xoma Technology Ltd Therapeutische verwendungen von antibakteriellen/durchlässigkeitserhöhenden proteinprodukten
WO1994020129A1 (en) * 1993-03-12 1994-09-15 Xoma Corporation Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
ATE169304T1 (de) * 1993-03-12 1998-08-15 Xoma Corp Biologisch aktive peptide aus funktionellen domaenen des bakteriziden/ die permeabilitaet erhoehenden proteins und ihre verwendung
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products

Also Published As

Publication number Publication date
EP0754049A1 (de) 1997-01-22
US5627153A (en) 1997-05-06
MX9602570A (es) 1997-04-30
EP0754049B1 (de) 2002-04-03
HK1014158A1 (en) 1999-09-24
AU1679795A (en) 1995-08-01
AU703211B2 (en) 1999-03-18
JPH09508357A (ja) 1997-08-26
DE69526216D1 (de) 2002-05-08
CA2181165C (en) 2007-06-05
CN1112933C (zh) 2003-07-02
CA2181165A1 (en) 1995-07-20
WO1995019179A1 (en) 1995-07-20
ATE215379T1 (de) 2002-04-15
CN1140999A (zh) 1997-01-22

Similar Documents

Publication Publication Date Title
DE69526216T2 (de) Antifungaleverfahren und mitteln
AU3909497A (en) Anti-chlamydial methods and materials
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
NZ332721A (en) Use of bactericidal/permeability increasing (BPI) protein sometimes in conjunction with a thrombolytic agent to treat thrombotic disorders
SG147274A1 (en) Prevention and treatment of amyloidogenic disease
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
IL122386A0 (en) Anti-fungal and anti-bacterial histatin-based peptides
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
BR9707819A (pt) Imunogenos peptidicos
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ZA951974B (en) Bradykinin antagonist peptides incorporating N-subsituted glycines
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
EP1374887A4 (de) Neue mittel zur linderung von motorischen störungen
DE69601154D1 (de) Zubereitungen für die Behandlung von Hepatitis C
BR9611904A (pt) Dioxidos de ditiazol
ATE247467T1 (de) Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee